Global Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	168 Pages	TechNavio	August, 2024	INF19178801

Best Price Guarantee
Price	from $2,500
Length	168 Pages
Publisher	TechNavio
Published Date	August, 2024
SKU	INF19178801

Global Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028

Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028

The chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7193.4 mn during 2023-2028, accelerating at a CAGR of 6.24% during the forecast period. The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.

Technavio's chronic obstructive pulmonary disease drugs market is segmented as below:

By Product

Combination therapy
Monotherapy

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.

The report on the chronic obstructive pulmonary disease drugs market covers the following areas:

Chronic obstructive pulmonary disease drugs market sizing
Chronic obstructive pulmonary disease drugs market forecast
Chronic obstructive pulmonary disease drugs market industry analysis

The vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., Exela Pharma Sciences LLC, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Innoviva, Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Philip Morris International Inc., SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., and Viatris Inc.. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by Product; Executive Summary - Chart on Market Segmentation by Distribution Channel; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Chronic Obstructive Pulmonary Disease Drugs Market 2018 - 2022; Historic Market Size - Data Table on Global Chronic Obstructive Pulmonary Disease Drugs Market 2018 - 2022 ($ million); 4.2 Product segment analysis 2018 - 2022; Historic Market Size - Product Segment 2018 - 2022 ($ million); 4.3 Distribution Channel segment analysis 2018 - 2022; Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); 4.4 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.5 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product: 6.1 Market segments; Chart on Product - Market share 2023-2028 (%); Data Table on Product - Market share 2023-2028 (%); 6.2 Comparison by Product; Chart on Comparison by Product; Data Table on Comparison by Product; 6.3 Combination therapy - Market size and forecast 2023-2028; Chart on Combination therapy - Market size and forecast 2023-2028 ($ million); Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million); Chart on Combination therapy - Year-over-year growth 2023-2028 (%); Data Table on Combination therapy - Year-over-year growth 2023-2028 (%); 6.4 Monotherapy - Market size and forecast 2023-2028; Chart on Monotherapy - Market size and forecast 2023-2028 ($ million); Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million); Chart on Monotherapy - Year-over-year growth 2023-2028 (%); Data Table on Monotherapy - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Product; Market opportunity by Product ($ million); Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Distribution Channel: 7.1 Market segments; Chart on Distribution Channel - Market share 2023-2028 (%); Data Table on Distribution Channel - Market share 2023-2028 (%); 7.2 Comparison by Distribution Channel; Chart on Comparison by Distribution Channel; Data Table on Comparison by Distribution Channel; 7.3 Hospital pharmacies - Market size and forecast 2023-2028; Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); 7.4 Retail pharmacies - Market size and forecast 2023-2028; Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); 7.5 Online pharmacies - Market size and forecast 2023-2028; Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million); Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million); Chart on Online pharmacies - Year-over-year growth 2023-2028 (%); Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%); 7.6 Market opportunity by Distribution Channel; Market opportunity by Distribution Channel ($ million); Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Chart on Market share By Geographical Landscape 2023-2028 (%); Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 UK - Market size and forecast 2023-2028; Chart on UK - Market size and forecast 2023-2028 ($ million); Data Table on UK - Market size and forecast 2023-2028 ($ million); Chart on UK - Year-over-year growth 2023-2028 (%); Data Table on UK - Year-over-year growth 2023-2028 (%); 9.9 Canada - Market size and forecast 2023-2028; Chart on Canada - Market size and forecast 2023-2028 ($ million); Data Table on Canada - Market size and forecast 2023-2028 ($ million); Chart on Canada - Year-over-year growth 2023-2028 (%); Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.10 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.11 Japan - Market size and forecast 2023-2028; Chart on Japan - Market size and forecast 2023-2028 ($ million); Data Table on Japan - Market size and forecast 2023-2028 ($ million); Chart on Japan - Year-over-year growth 2023-2028 (%); Data Table on Japan - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Opportunity/Restraints: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 10.4 Market opportunities/restraints
11 Competitive Landscape: 11.1 Overview; 11.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 11.3 Landscape disruption; Overview on factors of disruption; 11.4 Industry risks; Impact of key risks on business
12 Competitive Analysis: 12.1 Companies profiled; Companies covered; 12.2 Market positioning of companies; Matrix on companies position and classification; 12.3 AstraZeneca Plc; AstraZeneca Plc - Overview; AstraZeneca Plc - Product / Service; AstraZeneca Plc - Key news; AstraZeneca Plc - Key offerings; 12.4 Boehringer Ingelheim International GmbH; Boehringer Ingelheim International GmbH - Overview; Boehringer Ingelheim International GmbH - Product / Service; Boehringer Ingelheim International GmbH - Key news; Boehringer Ingelheim International GmbH - Key offerings; 12.5 Cadila Pharmaceuticals Ltd.; Cadila Pharmaceuticals Ltd. - Overview; Cadila Pharmaceuticals Ltd. - Product / Service; Cadila Pharmaceuticals Ltd. - Key offerings; 12.6 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; 12.7 Exela Pharma Sciences LLC; Exela Pharma Sciences LLC - Overview; Exela Pharma Sciences LLC - Product / Service; Exela Pharma Sciences LLC - Key offerings; 12.8 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; 12.9 Lupin Ltd.; Lupin Ltd. - Overview; Lupin Ltd. - Business segments; Lupin Ltd. - Key news; Lupin Ltd. - Key offerings; Lupin Ltd. - Segment focus; 12.10 Merck and Co. Inc.; Merck and Co. Inc. - Overview; Merck and Co. Inc. - Business segments; Merck and Co. Inc. - Key news; Merck and Co. Inc. - Key offerings; Merck and Co. Inc. - Segment focus; 12.11 Mundipharma International Ltd.; Mundipharma International Ltd. - Overview; Mundipharma International Ltd. - Product / Service; Mundipharma International Ltd. - Key offerings; 12.12 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; 12.13 SHIONOGI Co. Ltd.; SHIONOGI Co. Ltd. - Overview; SHIONOGI Co. Ltd. - Product / Service; SHIONOGI Co. Ltd. - Key offerings; 12.14 Sumitomo Pharma Co. Ltd.; Sumitomo Pharma Co. Ltd. - Overview; Sumitomo Pharma Co. Ltd. - Business segments; Sumitomo Pharma Co. Ltd. - Key news; Sumitomo Pharma Co. Ltd. - Key offerings; Sumitomo Pharma Co. Ltd. - Segment focus; 12.15 Teva Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd. - Overview; Teva Pharmaceutical Industries Ltd. - Business segments; Teva Pharmaceutical Industries Ltd. - Key news; Teva Pharmaceutical Industries Ltd. - Key offerings; Teva Pharmaceutical Industries Ltd. - Segment focus; 12.16 Theravance Biopharma Inc.; Theravance Biopharma Inc. - Overview; Theravance Biopharma Inc. - Product / Service; Theravance Biopharma Inc. - Key offerings; 12.17 Viatris Inc.; Viatris Inc. - Overview; Viatris Inc. - Business segments; Viatris Inc. - Key news; Viatris Inc. - Key offerings; Viatris Inc. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 13.3 Currency conversion rates for US$; Currency conversion rates for US$; 13.4 Research methodology; Research methodology; 13.5 Data procurement; Information sources; 13.6 Data validation; Data validation; 13.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 13.8 Data synthesis; Data synthesis; 360 degree market analysis; 360 degree market analysis; 13.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Product; Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Parent Market; Exhibits11: Data Table on - Parent Market; Exhibits12: Market characteristics analysis; Exhibits13: Value Chain Analysis; Exhibits14: Offerings of companies included in the market definition; Exhibits15: Market segments; Exhibits16: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits18: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits20: Historic Market Size - Data Table on Global Chronic Obstructive Pulmonary Disease Drugs Market 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Product Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits24: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits25: Five forces analysis - Comparison between 2023 and 2028; Exhibits26: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits28: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits29: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits30: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits31: Chart on Market condition - Five forces 2023 and 2028; Exhibits32: Chart on Product - Market share 2023-2028 (%); Exhibits33: Data Table on Product - Market share 2023-2028 (%); Exhibits34: Chart on Comparison by Product; Exhibits35: Data Table on Comparison by Product; Exhibits36: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million); Exhibits37: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million); Exhibits38: Chart on Combination therapy - Year-over-year growth 2023-2028 (%); Exhibits39: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%); Exhibits40: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million); Exhibits41: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million); Exhibits42: Chart on Monotherapy - Year-over-year growth 2023-2028 (%); Exhibits43: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%); Exhibits44: Market opportunity by Product ($ million); Exhibits45: Data Table on Market opportunity by Product ($ million); Exhibits46: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibits47: Data Table on Distribution Channel - Market share 2023-2028 (%); Exhibits48: Chart on Comparison by Distribution Channel; Exhibits49: Data Table on Comparison by Distribution Channel; Exhibits50: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits51: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits52: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits53: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits54: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits55: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits56: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits57: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits58: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits59: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits60: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibits61: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibits62: Market opportunity by Distribution Channel ($ million); Exhibits63: Data Table on Market opportunity by Distribution Channel ($ million); Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits65: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits66: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits67: Chart on Geographic comparison; Exhibits68: Data Table on Geographic comparison; Exhibits69: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits70: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits71: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits72: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits73: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits74: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits75: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits76: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits77: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits85: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits86: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits87: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits88: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits89: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits90: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits91: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits92: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits93: Chart on Canada - Market size and forecast 2023-2028 ($ million); Exhibits94: Data Table on Canada - Market size and forecast 2023-2028 ($ million); Exhibits95: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits96: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits97: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits98: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits99: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits100: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits101: Chart on Japan - Market size and forecast 2023-2028 ($ million); Exhibits102: Data Table on Japan - Market size and forecast 2023-2028 ($ million); Exhibits103: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibits104: Data Table on Japan - Year-over-year growth 2023-2028 (%); Exhibits105: Market opportunity By Geographical Landscape ($ million); Exhibits106: Data Tables on Market opportunity By Geographical Landscape ($ million); Exhibits107: Impact of drivers and challenges in 2023 and 2028; Exhibits108: Overview on criticality of inputs and factors of differentiation; Exhibits109: Overview on factors of disruption; Exhibits110: Impact of key risks on business; Exhibits111: Companies covered; Exhibits112: Matrix on companies position and classification; Exhibits113: AstraZeneca Plc - Overview; Exhibits114: AstraZeneca Plc - Product / Service; Exhibits115: AstraZeneca Plc - Key news; Exhibits116: AstraZeneca Plc - Key offerings; Exhibits117: Boehringer Ingelheim International GmbH - Overview; Exhibits118: Boehringer Ingelheim International GmbH - Product / Service; Exhibits119: Boehringer Ingelheim International GmbH - Key news; Exhibits120: Boehringer Ingelheim International GmbH - Key offerings; Exhibits121: Cadila Pharmaceuticals Ltd. - Overview; Exhibits122: Cadila Pharmaceuticals Ltd. - Product / Service; Exhibits123: Cadila Pharmaceuticals Ltd. - Key offerings; Exhibits124: Cipla Inc. - Overview; Exhibits125: Cipla Inc. - Business segments; Exhibits126: Cipla Inc. - Key news; Exhibits127: Cipla Inc. - Key offerings; Exhibits128: Cipla Inc. - Segment focus; Exhibits129: Exela Pharma Sciences LLC - Overview; Exhibits130: Exela Pharma Sciences LLC - Product / Service; Exhibits131: Exela Pharma Sciences LLC - Key offerings; Exhibits132: GlaxoSmithKline Plc - Overview; Exhibits133: GlaxoSmithKline Plc - Business segments; Exhibits134: GlaxoSmithKline Plc - Key news; Exhibits135: GlaxoSmithKline Plc - Key offerings; Exhibits136: GlaxoSmithKline Plc - Segment focus; Exhibits137: Lupin Ltd. - Overview; Exhibits138: Lupin Ltd. - Business segments; Exhibits139: Lupin Ltd. - Key news; Exhibits140: Lupin Ltd. - Key offerings; Exhibits141: Lupin Ltd. - Segment focus; Exhibits142: Merck and Co. Inc. - Overview; Exhibits143: Merck and Co. Inc. - Business segments; Exhibits144: Merck and Co. Inc. - Key news; Exhibits145: Merck and Co. Inc. - Key offerings; Exhibits146: Merck and Co. Inc. - Segment focus; Exhibits147: Mundipharma International Ltd. - Overview; Exhibits148: Mundipharma International Ltd. - Product / Service; Exhibits149: Mundipharma International Ltd. - Key offerings; Exhibits150: Novartis AG - Overview; Exhibits151: Novartis AG - Business segments; Exhibits152: Novartis AG - Key news; Exhibits153: Novartis AG - Key offerings; Exhibits154: Novartis AG - Segment focus; Exhibits155: SHIONOGI Co. Ltd. - Overview; Exhibits156: SHIONOGI Co. Ltd. - Product / Service; Exhibits157: SHIONOGI Co. Ltd. - Key offerings; Exhibits158: Sumitomo Pharma Co. Ltd. - Overview; Exhibits159: Sumitomo Pharma Co. Ltd. - Business segments; Exhibits160: Sumitomo Pharma Co. Ltd. - Key news; Exhibits161: Sumitomo Pharma Co. Ltd. - Key offerings; Exhibits162: Sumitomo Pharma Co. Ltd. - Segment focus; Exhibits163: Teva Pharmaceutical Industries Ltd. - Overview; Exhibits164: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibits165: Teva Pharmaceutical Industries Ltd. - Key news; Exhibits166: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibits167: Teva Pharmaceutical Industries Ltd. - Segment focus; Exhibits168: Theravance Biopharma Inc. - Overview; Exhibits169: Theravance Biopharma Inc. - Product / Service; Exhibits170: Theravance Biopharma Inc. - Key offerings; Exhibits171: Viatris Inc. - Overview; Exhibits172: Viatris Inc. - Business segments; Exhibits173: Viatris Inc. - Key news; Exhibits174: Viatris Inc. - Key offerings; Exhibits175: Viatris Inc. - Segment focus; Exhibits176: Inclusions checklist; Exhibits177: Exclusions checklist; Exhibits178: Currency conversion rates for US$; Exhibits179: Research methodology; Exhibits180: Information sources; Exhibits181: Data validation; Exhibits182: Validation techniques employed for market sizing; Exhibits183: Data synthesis; Exhibits184: 360 degree market analysis; Exhibits185: List of abbreviations